Department of Vermont Health Access
Pharmacy Benefits Management Program
*DUR Board Meeting Agenda*

April 15, 2014  6:00 – 8:15 p.m.
*** Please note new times ***

1. **Executive Session** 6:00 - 6:15
   - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements
     (as provided by 33 VSA § 1998(f)(2))

2. **Introductions and Approval of DUR Board Minutes** 6:15 - 6:20
   (Public Comment Prior to Board Action)

3. **DVHA Pharmacy Administration Updates** 6:20 - 6:25
   - Updates

4. **Medical Director Update** 6:25 - 6:30
   - Clinical Programs Update
   - Prescriber Comments

5. **Follow-up Items from Previous Meetings** 6:30 – 7:00
   - Dexilant® (dexlansoprazole)
   - Hepatitis C Medications
   - Xyrem® (Sodium Oxybate)

6. **RetroDUR/DUR** 7:00 – 7:15
   - Mental Health Medications in Children, SFY 2009, 2011 and 2013

7. **Clinical Update: Drug Reviews** 7:15 – 7:40
   (Public comment prior to Board action)

   **Abbreviated New Drug Reviews**
   - Aciphex® Sprinkles (rabeprazole) DR Capsules
   - Bethikis® (tobramycin) Ampule for Inhalation
   - Glycate® (glycopyrrolate) Oral Tablet

   **Full New Drug Reviews**
   - Adempas® (riociguat) Oral Tablet
   - Brintellix® (vortioxetine) Oral Tablet
   - Fetzima® (levomilnacipran) ER Oral Capsule
8. Therapeutic Drug Classes – Periodic Review 7:40 – 8:00
(Public comment prior to Board action)
- Analgesics: Topical NSAID
- Anticoagulants: Oral (see stroke prevention below)
- Antihypertensives: Beta Blockers
- Antihypertensives: Calcium Channel Blockers
- Dermatological: Antifungals
- Immunomodulators (new indications)
- Platelet Aggregation Inhibitors
- Smoking Cessation Products

9. Clinical Update: New/Updated Clinical Guidelines 8:00– 8:05
(Public comment prior to Board action)
- American Academy of Neurology (AAN) Guidelines on Stroke Prevention in Nonvalvular Atrial Fibrillation (NVAF)

10. New Managed Therapeutic Drug Classes 8:05– 8:05
(Public comment prior to Board action)
- None

11. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products 8:05 – 8:10
(Public comment prior to Board action)
- Gastrointestinal: Proton Pump Inhibitors (compound suspension kits)
- Smoking Cessation Products (see therapeutic class review above)

12. General Announcements 8:10– 8:15
Selected FDA Safety Alerts
- FDA Drug Safety Communication: FDA clarifies Warning about Pediatric Use of Revatio® (sildenafil) for Pulmonary Arterial Hypertension

13. Adjourn 8:15